Clinical Trial Update: Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of gemcitabine, paclitaxel, and doxorubicin in metastatic or unresectable bladder cancer with decreased kidney function; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder
• Urothelial Cancer of the Bladder

Drugs mentioned

• Doxorubicin (doxorubicin)
• Gemcitabine (Gemcitabine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED | Results posted: 2020-10-09